WO2013067300A1 - Méthode de traitement - Google Patents
Méthode de traitement Download PDFInfo
- Publication number
- WO2013067300A1 WO2013067300A1 PCT/US2012/063239 US2012063239W WO2013067300A1 WO 2013067300 A1 WO2013067300 A1 WO 2013067300A1 US 2012063239 W US2012063239 W US 2012063239W WO 2013067300 A1 WO2013067300 A1 WO 2013067300A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- methyl
- mmol
- indazole
- cycloalkyl
- Prior art date
Links
- 0 CC(C)[n](c1cc(-c(cc2)cc(*3=C)c2NC3=O)c2)ncc1c2C(NCC1=C(C)C=C(C)NC1=O)=O Chemical compound CC(C)[n](c1cc(-c(cc2)cc(*3=C)c2NC3=O)c2)ncc1c2C(NCC1=C(C)C=C(C)NC1=O)=O 0.000 description 1
- MFJMHYUAPUQHMO-UHFFFAOYSA-N CC(C)[n](c1cc(-c2c[nH]nc2)c2)nc(C)c1c2C(O)=O Chemical compound CC(C)[n](c1cc(-c2c[nH]nc2)c2)nc(C)c1c2C(O)=O MFJMHYUAPUQHMO-UHFFFAOYSA-N 0.000 description 1
- SURSUMAXQYLELC-UHFFFAOYSA-N CC(C)[n](c1cc(N2CCC(CN(C)C)CC2)c2)ncc1c2C(OC)=O Chemical compound CC(C)[n](c1cc(N2CCC(CN(C)C)CC2)c2)ncc1c2C(OC)=O SURSUMAXQYLELC-UHFFFAOYSA-N 0.000 description 1
- RVEQJTVJDKNTJC-UHFFFAOYSA-N CC(C)[n](c1cc(S(Cl)(=O)=O)c2)ncc1c2C(OC)=O Chemical compound CC(C)[n](c1cc(S(Cl)(=O)=O)c2)ncc1c2C(OC)=O RVEQJTVJDKNTJC-UHFFFAOYSA-N 0.000 description 1
- JMPVBYGPJPCOEN-UHFFFAOYSA-N CC(C)[n](c1cc([N+](O)=O)c2)ncc1c2C(OC)=O Chemical compound CC(C)[n](c1cc([N+](O)=O)c2)ncc1c2C(OC)=O JMPVBYGPJPCOEN-UHFFFAOYSA-N 0.000 description 1
- YZZXPTKTMOTJOY-UHFFFAOYSA-N CC(C)[n]1nc(C)c(c(C(OC)=O)c2)c1cc2Br Chemical compound CC(C)[n]1nc(C)c(c(C(OC)=O)c2)c1cc2Br YZZXPTKTMOTJOY-UHFFFAOYSA-N 0.000 description 1
- YJMDLNMTFKVIFD-UHFFFAOYSA-N CC(C=C(C)N1)=C(CNC(c2c(cn[n]3C4CCCC4)c3cc(-c(cc3)ccc3F)c2)=O)C1=O Chemical compound CC(C=C(C)N1)=C(CNC(c2c(cn[n]3C4CCCC4)c3cc(-c(cc3)ccc3F)c2)=O)C1=O YJMDLNMTFKVIFD-UHFFFAOYSA-N 0.000 description 1
- FWBYCPAATXJYOH-UHFFFAOYSA-N CC(C=C(C)N1)=C(CNC(c2c(cn[n]3C4CCCC4)c3cc(-c3ccc(N4CCNCC4)nc3)c2)=O)C1=O Chemical compound CC(C=C(C)N1)=C(CNC(c2c(cn[n]3C4CCCC4)c3cc(-c3ccc(N4CCNCC4)nc3)c2)=O)C1=O FWBYCPAATXJYOH-UHFFFAOYSA-N 0.000 description 1
- ZOYKFUMSDCMURV-UHFFFAOYSA-N CC(C=C(C)N1)=C(CNC(c2c(cn[n]3C4CCCC4)c3cc(-c3ccnc(N4CCN(C)CC4)c3)c2)=O)C1=O Chemical compound CC(C=C(C)N1)=C(CNC(c2c(cn[n]3C4CCCC4)c3cc(-c3ccnc(N4CCN(C)CC4)c3)c2)=O)C1=O ZOYKFUMSDCMURV-UHFFFAOYSA-N 0.000 description 1
- RFXJKNSXOOYXNC-UHFFFAOYSA-N CC(C=C(C)N1)=C(CNC(c2cc(-c(cc3)cnc3N3CCOCC3)cc3c2cn[n]3C2CCCC2)=O)C1=O Chemical compound CC(C=C(C)N1)=C(CNC(c2cc(-c(cc3)cnc3N3CCOCC3)cc3c2cn[n]3C2CCCC2)=O)C1=O RFXJKNSXOOYXNC-UHFFFAOYSA-N 0.000 description 1
- PBGAZQLIFHVHCX-UHFFFAOYSA-N CC(N1)=CC(C2CCCCC2)=C(CN)C1=O Chemical compound CC(N1)=CC(C2CCCCC2)=C(CN)C1=O PBGAZQLIFHVHCX-UHFFFAOYSA-N 0.000 description 1
- GJVSESJCRXRKCF-UHFFFAOYSA-N CC(N1)=CC(c2ccncc2)=C(C=N)C1=O Chemical compound CC(N1)=CC(c2ccncc2)=C(C=N)C1=O GJVSESJCRXRKCF-UHFFFAOYSA-N 0.000 description 1
- SYJIGABLKMXEDC-UHFFFAOYSA-N CCC(C)C(C=C(C)N1)=C(CN)C1=O Chemical compound CCC(C)C(C=C(C)N1)=C(CN)C1=O SYJIGABLKMXEDC-UHFFFAOYSA-N 0.000 description 1
- UFDWGLLPXTZJIU-UHFFFAOYSA-N CCC(C)C(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(Br)c2)=O)C1=O Chemical compound CCC(C)C(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(Br)c2)=O)C1=O UFDWGLLPXTZJIU-UHFFFAOYSA-N 0.000 description 1
- XYYRYUBNYPGREO-UHFFFAOYSA-N CCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c3ccc(N4CCN(C)CC4)nc3)c2)=O)C1=O Chemical compound CCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c3ccc(N4CCN(C)CC4)nc3)c2)=O)C1=O XYYRYUBNYPGREO-UHFFFAOYSA-N 0.000 description 1
- FPVLQEDZOPAPMJ-UHFFFAOYSA-N CCCC(C=C(C)N1)=C(CNC(c2c(c(C)n[n]3C(C)C)c3cc(-c3ccc(N(C)C)nc3)c2)=O)C1=O Chemical compound CCCC(C=C(C)N1)=C(CNC(c2c(c(C)n[n]3C(C)C)c3cc(-c3ccc(N(C)C)nc3)c2)=O)C1=O FPVLQEDZOPAPMJ-UHFFFAOYSA-N 0.000 description 1
- ABSIVOMTAQHWAX-UHFFFAOYSA-N CCCC(C=C(C)N1)=C(CNC(c2c(c(C)n[n]3C(C)C)c3cc(-c3cccnc3)c2)=O)C1=O Chemical compound CCCC(C=C(C)N1)=C(CNC(c2c(c(C)n[n]3C(C)C)c3cc(-c3cccnc3)c2)=O)C1=O ABSIVOMTAQHWAX-UHFFFAOYSA-N 0.000 description 1
- CPVDATAVZRCUKH-UHFFFAOYSA-N CCCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c(cc3)cnc3N(C)C)c2)=O)C1=O Chemical compound CCCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c(cc3)cnc3N(C)C)c2)=O)C1=O CPVDATAVZRCUKH-UHFFFAOYSA-N 0.000 description 1
- VVUGKXZXDXBCIJ-UHFFFAOYSA-N CCCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c3c(C)nccc3)c2)=O)C1=O Chemical compound CCCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c3c(C)nccc3)c2)=O)C1=O VVUGKXZXDXBCIJ-UHFFFAOYSA-N 0.000 description 1
- TXMUSRGMRSEYEF-UHFFFAOYSA-N CCCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c3c[nH]nc3)c2)=O)C1=O Chemical compound CCCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c3c[nH]nc3)c2)=O)C1=O TXMUSRGMRSEYEF-UHFFFAOYSA-N 0.000 description 1
- NTPOMMRDODEGDA-UHFFFAOYSA-N CCCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c3cncnc3)c2)=O)C1=O Chemical compound CCCC(C=C(C)N1)=C(CNC(c2c(cn[n]3C(C)C)c3cc(-c3cncnc3)c2)=O)C1=O NTPOMMRDODEGDA-UHFFFAOYSA-N 0.000 description 1
- DXUUJILVHXQDCV-UHFFFAOYSA-N Cc(c([N+]([O-])=O)cc(Br)c1)c1C(O)=O Chemical compound Cc(c([N+]([O-])=O)cc(Br)c1)c1C(O)=O DXUUJILVHXQDCV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
Abstract
La présente invention concerne une méthode de traitement de maladies immunes inflammatoires médiées par les lymphocytes T ou de maladies d'hypersensibilité médiées par les lymphocytes T, la méthode consistant à administrer à un être humain nécessitant ce traitement une quantité efficace d'un composé qui inhibe EZH2 et/ou EZH1, ou un sel pharmaceutiquement acceptable de ce composé.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161555656P | 2011-11-04 | 2011-11-04 | |
US61/555,656 | 2011-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013067300A1 true WO2013067300A1 (fr) | 2013-05-10 |
Family
ID=48192802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/063239 WO2013067300A1 (fr) | 2011-11-04 | 2012-11-02 | Méthode de traitement |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013067300A1 (fr) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015506985A (ja) * | 2012-02-10 | 2015-03-05 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. | メチル基変更酵素の調節物質、組成物及びその使用 |
WO2015077194A1 (fr) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibiteurs de la lysine méthyltransférase |
US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US20150344459A1 (en) * | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
US9527837B2 (en) | 2014-12-05 | 2016-12-27 | Eli Lilly And Company | Inhibitors of EZH2 |
US9718838B2 (en) | 2015-08-27 | 2017-08-01 | Eli Lilly And Company | Inhibitors of EZH2 |
US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
WO2018210296A1 (fr) * | 2017-05-18 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | Utilisation d'un inhibiteur d'ezh2 combiné à un inhibiteur de btk dans la préparation d'un médicament pour le traitement d'une tumeur |
WO2018210302A1 (fr) | 2017-05-18 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | Formes cristallines du chlore libre dérivé du benzofurane et son procédé de préparation |
US10239843B2 (en) | 2014-12-12 | 2019-03-26 | Cancer Research Technology Limited | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG |
US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
US10508086B2 (en) | 2014-12-19 | 2019-12-17 | Cancer Research Technology Limited | PARG inhibitory compounds |
US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
US10633371B2 (en) | 2016-04-22 | 2020-04-28 | Dana-Farber Cancer Institute, Inc. | EZH2 inhibitors and uses thereof |
US10759787B2 (en) | 2015-11-19 | 2020-09-01 | Jiangsu Hengrui Medicine Co., Ltd. | Benzofuran derivative, preparation method thereof and use thereof in medicine |
EP3885343A1 (fr) | 2014-11-06 | 2021-09-29 | Dana-Farber Cancer Institute, Inc. | Composés d'indole comme inhibiteurs de ezh2 et utilisations associées |
WO2023244918A1 (fr) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Agents de dégradation bifonctionnels de quinolone bcl6 |
WO2023244917A1 (fr) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Agents dégradant bcl6 hétérobifonctionnels 1,8-naphthyridin-2-one |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005034845A2 (fr) * | 2003-09-12 | 2005-04-21 | Supergen, Inc. | Compositions et methodes de traitement du cancer |
WO2007053114A1 (fr) * | 2005-10-31 | 2007-05-10 | S*Bio Pte Ltd | Méthode permettant de prévoir une réponse aux inhibiteurs hdac |
WO2010090723A2 (fr) * | 2009-02-04 | 2010-08-12 | University Of Georgia Research Foundation, Inc. | Procédés d'inhibition de fibrogenèse et de traitement de maladie fibrotique |
US20110064664A1 (en) * | 2007-10-08 | 2011-03-17 | The Board Of Regents Of The University Of Texas System | Methods and compositions involving chitosan nanoparticles |
-
2012
- 2012-11-02 WO PCT/US2012/063239 patent/WO2013067300A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005034845A2 (fr) * | 2003-09-12 | 2005-04-21 | Supergen, Inc. | Compositions et methodes de traitement du cancer |
WO2007053114A1 (fr) * | 2005-10-31 | 2007-05-10 | S*Bio Pte Ltd | Méthode permettant de prévoir une réponse aux inhibiteurs hdac |
US20110064664A1 (en) * | 2007-10-08 | 2011-03-17 | The Board Of Regents Of The University Of Texas System | Methods and compositions involving chitosan nanoparticles |
WO2010090723A2 (fr) * | 2009-02-04 | 2010-08-12 | University Of Georgia Research Foundation, Inc. | Procédés d'inhibition de fibrogenèse et de traitement de maladie fibrotique |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9409865B2 (en) | 2011-11-18 | 2016-08-09 | Constellation_Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9980952B2 (en) | 2012-02-10 | 2018-05-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
USRE47428E1 (en) | 2012-02-10 | 2019-06-11 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
JP2015506985A (ja) * | 2012-02-10 | 2015-03-05 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. | メチル基変更酵素の調節物質、組成物及びその使用 |
US9371331B2 (en) | 2012-02-10 | 2016-06-21 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9469646B2 (en) | 2012-02-10 | 2016-10-18 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US10016405B2 (en) | 2012-02-10 | 2018-07-10 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US10150759B2 (en) | 2012-12-21 | 2018-12-11 | Epizyme, Inc. | 1,4-pyridone bicycic heteroaryl compounds |
US20150344459A1 (en) * | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
US9701666B2 (en) * | 2012-12-21 | 2017-07-11 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
US9822103B2 (en) | 2013-11-22 | 2017-11-21 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
WO2015077194A1 (fr) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibiteurs de la lysine méthyltransférase |
US11236082B2 (en) | 2014-11-06 | 2022-02-01 | Dana-Farber Cancer Institute, Inc. | EZH2 inhibitors and uses thereof |
EP3885343A1 (fr) | 2014-11-06 | 2021-09-29 | Dana-Farber Cancer Institute, Inc. | Composés d'indole comme inhibiteurs de ezh2 et utilisations associées |
US9527837B2 (en) | 2014-12-05 | 2016-12-27 | Eli Lilly And Company | Inhibitors of EZH2 |
US10239843B2 (en) | 2014-12-12 | 2019-03-26 | Cancer Research Technology Limited | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG |
US10995073B2 (en) | 2014-12-19 | 2021-05-04 | Cancer Research Technology Limited | PARG inhibitory compounds |
US10508086B2 (en) | 2014-12-19 | 2019-12-17 | Cancer Research Technology Limited | PARG inhibitory compounds |
US9718838B2 (en) | 2015-08-27 | 2017-08-01 | Eli Lilly And Company | Inhibitors of EZH2 |
US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
US11059811B2 (en) | 2015-11-19 | 2021-07-13 | Jiangsu Hengrui Medicine Co., Ltd. | Benzofuran derivative, preparation method thereof and use thereof in medicine |
US10759787B2 (en) | 2015-11-19 | 2020-09-01 | Jiangsu Hengrui Medicine Co., Ltd. | Benzofuran derivative, preparation method thereof and use thereof in medicine |
US10633371B2 (en) | 2016-04-22 | 2020-04-28 | Dana-Farber Cancer Institute, Inc. | EZH2 inhibitors and uses thereof |
US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
WO2018210302A1 (fr) | 2017-05-18 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | Formes cristallines du chlore libre dérivé du benzofurane et son procédé de préparation |
KR20200007851A (ko) * | 2017-05-18 | 2020-01-22 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 종양 치료용 약물의 제조에 있어서의 ezh2 억제제 및 btk 억제제의 조합물의 용도 |
US11065239B2 (en) | 2017-05-18 | 2021-07-20 | Jiangsu Hengrui Medicine Co., Ltd. | Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumor |
CN109937041A (zh) * | 2017-05-18 | 2019-06-25 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 |
US11155537B2 (en) | 2017-05-18 | 2021-10-26 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal of benzofuran derivative free base and preparation method |
RU2762893C2 (ru) * | 2017-05-18 | 2021-12-23 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли |
WO2018210296A1 (fr) * | 2017-05-18 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | Utilisation d'un inhibiteur d'ezh2 combiné à un inhibiteur de btk dans la préparation d'un médicament pour le traitement d'une tumeur |
CN109937041B (zh) * | 2017-05-18 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 |
KR102635949B1 (ko) | 2017-05-18 | 2024-02-14 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 종양 치료용 약물의 제조에 있어서의 ezh2 억제제 및 btk 억제제의 조합물의 용도 |
WO2023244918A1 (fr) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Agents de dégradation bifonctionnels de quinolone bcl6 |
WO2023244917A1 (fr) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Agents dégradant bcl6 hétérobifonctionnels 1,8-naphthyridin-2-one |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013067300A1 (fr) | Méthode de traitement | |
US9446041B2 (en) | Method of treatment | |
WO2013067302A1 (fr) | Méthode de traitement | |
US9402836B2 (en) | Indoles | |
US9018382B2 (en) | Indazoles | |
US9193722B2 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
WO2016180536A1 (fr) | Dérivés de quinoxaline substitués | |
CA2731432A1 (fr) | Inhibiteurs de la pyrazolopyridine kinase tricyclique | |
JP5769733B2 (ja) | ピラゾロピリジンキナーゼ阻害剤 | |
AU2009279611A1 (en) | Aminopyridine kinase inhibitors | |
EP2922823B1 (fr) | Inhibiteurs pyrimidines de pde10 | |
CA2787079A1 (fr) | Inhibiteurs de la pyrazolopyrazine kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12845516 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12845516 Country of ref document: EP Kind code of ref document: A1 |